Abstract submission is now closed.
Abstract submission deadlines
Date and time
Wednesday, 20 May 2020
*Monday, 17 August 2020
* A preliminary abstract indicating the data expected to be available by the late-breaking abstract deadline must be submitted online by 20 May 2020 and the intent to submit a late-breaking abstract check-box must be ticked.
Abstract submission categories
- Basic science
- Biliary tract cancer, incl. cholangiocarcinoma
- Biomarkers (agnostic)
- Breast cancer, early stage
- Breast cancer, locally advanced
- Breast cancer, metastatic
- CNS tumours
- Colorectal cancer
- Developmental therapeutics
- Endocrine tumours
- Genitourinary tumours, prostate
- Genitourinary tumours, non-prostate
- Gynaecological cancers
- Haematological malignancies
- Head and neck cancer, excluding thyroid
- Hepatocellular carcinoma (HCC)
- Investigational immunotherapy
- Melanoma and other skin tumours
- Neuroendocrine tumours
- New diagnostic tools
- NSCLC, early stage
- NSCLC, locally advanced
- NSCLC, metastatic
- Oesophagogastric cancer
- Palliative care
- Pancreatic cancer
- Public policy
- SARS-CoV-2 and cancer
- Supportive care
- Thoracic malignancies, other
- Thyroid cancer
- Translational research (agnostic)
- Tumour biology and pathology
- Cancer Nursing Education: Challenges and opportunities
- Cancer Nursing: Digital innovations in health
- Cancer Nursing: Leadership
- Cancer Nursing: Palliative and end-of-life care
- Cancer Nursing: Patient and occupational safety
- Cancer Nursing: Psychosocial care and survivorship
- Cancer Nursing: SARS-CoV-2 and cancer
- Cancer Nursing: Symptom management
- Cancer Nursing: Translating research into practice
Late-breaking abstracts (LBA)
Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 20 May 2020 will be considered for late-breaking status.
The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO 2020, and a pre-planned analysis must be scheduled between the regular submission deadline of 20 May 2020 and the late-breaking submission deadline of 17 August 2020.
The final late-breaking abstract deadline of 17 August 2020 is under no circumstances to be considered as an extension of the general submission deadline.
A preliminary abstract indicating the data expected to be available by the late-breaking abstract deadline must be submitted online by 20 May 2020 and the intent to submit a late-breaking abstract check-box must be ticked. The abstract must include the title, first author (with full contact details), objectives, rationale, methodology and anticipated data.
Trial in progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO 2020.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:
- Trial design
- Recruitment must have already begun or have been completed by the abstract submission deadline of 20 May 2020.
- Abstracts including results or preliminary data will be rejected.
- Trial in Progress abstracts will NOT be considered for Proffered Paper (oral) presentation or Mini Oral.
- Encore TiP abstracts will NOT be accepted.
Presentation options for accepted abstracts
The ESMO 2020 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
- Presidential Symposium – Oral presentations by authors of the very best submitted abstracts containing cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display sessions for review, discussion and questions. Rotated by category, posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work.
All accepted abstracts will be available after the outcome notification in the online programme and will be published after the Congress in the ESMO 2020 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
Abstract outcome notifications are expected to be sent to first authors by end July 2020.
Publication schedule for accepted abstracts
Date and time
Abstracts accepted as:
Monday, 14 September 2020
Abstracts accepted as:
Friday, 18 September 2020
Late-breaking abstracts (prefix ‘LBA’)
At the start of the official Congress session during which they are presented.
Abstracts and LBAs selected for inclusion in the ESMO Press Programme (suffix ‘PR’)
Published according to a dedicated schedule to be made available during the second week of September 2020
Both ESMO and EONS offer abstract presenters the possibility to apply for subsidised travel and accommodation to facilitate their attendance at the ESMO 2020 Congress. Based on the submission categories and eligibility criteria outlined below, a limited number of ESMO Merit Awards and one EONS Novice Research Dissemination Award are available upon application.